<bill session="116" type="s" number="1416" updated="2022-11-01T13:50:47Z">
  <state datetime="2019-06-27">REPORTED</state>
  <status>
    <unknown datetime="2019-06-27"/>
  </status>
  <introduced datetime="2019-05-09"/>
  <titles>
    <title type="display">Affordable Prescriptions for Patients Act of 2019</title>
    <title type="short" as="reported to senate">Affordable Prescriptions for Patients Act of 2019</title>
    <title type="short" as="introduced">Affordable Prescriptions for Patients Act of 2019</title>
    <title type="official" as="introduced">A bill to amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="C001056"/>
  <cosponsors>
    <cosponsor bioguide_id="B001277" joined="2019-05-09"/>
    <cosponsor bioguide_id="C001047" joined="2019-05-15"/>
    <cosponsor bioguide_id="D000563" joined="2019-06-26"/>
    <cosponsor bioguide_id="F000463" joined="2019-11-13"/>
    <cosponsor bioguide_id="H001089" joined="2019-06-04"/>
    <cosponsor bioguide_id="K000393" joined="2019-06-03"/>
    <cosponsor bioguide_id="K000383" joined="2019-07-24"/>
    <cosponsor bioguide_id="M001197" joined="2019-11-13"/>
    <cosponsor bioguide_id="M001111" joined="2019-05-22"/>
    <cosponsor bioguide_id="P000595" joined="2019-09-25"/>
    <cosponsor bioguide_id="S001217" joined="2019-06-03"/>
    <cosponsor bioguide_id="S001203" joined="2019-09-12"/>
    <cosponsor bioguide_id="T000461" joined="2019-11-21"/>
  </cosponsors>
  <actions>
    <action datetime="2019-05-09">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-05-09" state="REFERRED">
      <text>Read twice and referred to the Committee on the Judiciary.</text>
    </action>
    <action datetime="2019-06-27" state="REPORTED">
      <text>Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.</text>
    </action>
    <action datetime="2019-06-28">
      <text>Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.</text>
    </action>
    <calendar datetime="2019-06-28" calendar="Senate Legislative" under="General Orders" number="132">
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.</text>
    </calendar>
  </actions>
  <committees>
    <committee code="SSJU" name="Senate Judiciary" subcommittee="" activity="Reporting, Markup, Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="3991" relation="unknown"/>
    <bill session="116" type="h" number="4398" relation="unknown"/>
    <bill session="116" type="h" number="5133" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Commerce"/>
    <term name="Administrative remedies"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Consumer affairs"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Intellectual property"/>
    <term name="Judicial review and appeals"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-03-17T17:44:02Z" status="Reported to Senate">Affordable Prescriptions for Patients Act of 2019 This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a hard switch or a soft switch. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration&#8217;s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A follow-on product is a changed, modified, or reformulated version of a manufacturer&#8217;s already-approved drug or biological product that still treats the same medical condition. A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product. A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition. This bill also limits the number of patents that may be included in infringement claims brought by approved biological product license holders against applicants for a biosimilar product license.</summary>
</bill>
